Full Press Release Details
Accessibility: Skip TopNav
Summit to Present Company Overview at JMP Securities Healthcare Conference
June 19, 2014 07:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or the 'Company')
SUMMIT TO PRESENT COMPANY OVERVIEW AT JMP SECURITIES HEALTHCARE CONFERENCE
Oxford, UK, 19 June 2014 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces that it will be presenting at the JMP Securities Healthcare Conference in New York on Wednesday, 25 June at 14:00 EST (19:00 BST).
Mr Glyn Edwards, Summit's Chief Executive Officer, will present a review of the Company's utrophin modulation programme for the treatment of the fatal muscle wasting disease DMD and he will also review Summit's selective antibiotic in development for the treatment of CDI.
A copy of the presentation will be available immediately after the event on the Investor Relations section of the Company's website, www.summitplc.com.
Summit is an Oxford, UK based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is quoted on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 951 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 77148 7900 |
| N+1 Singer (Broker) Aubrey Powell / Will Goode | Tel: +44 (0)20 7496 3000 |
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
| MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781 235 3060 |